Nutriband Inc.
Nutriband Inc.
Your view on NTRBW
Overview
What the company does, where it operates, and who runs it.
About Nutriband Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gareth Sheridan
- Headquarters
- 121 South Orange Avenue, Orlando, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gareth Sheridan
- Headquarters
- 121 South Orange Avenue, Orlando, FL, US
Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system.
This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices.
Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Nutriband Inc. from FRC's valuation model, read against the market price. NTRBW last traded at $0.55; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Nutriband Inc.. Starting points for Nutriband Inc.: EPS -$0.57, beta 1.97 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Nutriband Inc.. Nutriband Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Nutriband Inc.. Trailing twelve-month EPS for Nutriband Inc. stands at -$0.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrJul 2022 | Next QtrOct 2022 | Current YearFY Jan 2027 | Next YearFY Jan 2028 |
|---|---|---|---|---|
| Avg. estimate | -$0.04 | -$0.04 | $1.57 | $3.66 |
| Low estimate | -$0.04 | -$0.04 | $1.57 | $3.66 |
| High estimate | -$0.04 | -$0.04 | $1.57 | $3.66 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | — | -$2.581 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrJul 2022 | Next QtrOct 2022 | Current YearFY Jan 2027 | Next YearFY Jan 2028 |
|---|---|---|---|---|
| Avg. estimate | $465000.00 | $433500.00 | $95.41M | $180.41M |
| Low estimate | $465000.00 | $433500.00 | $95.41M | $180.41M |
| High estimate | $465000.00 | $433500.00 | $95.41M | $180.41M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | — | — | $2.04M | — |
| Growth | — | — | +4584.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Nutriband Inc.. Nutriband Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- BOLDBoundless Bio, Inc.Biotechnology$57M
- CVKDCadrenal Therapeutics, Inc. Common StockBiotechnology$5M
- IBIOiBio, Inc.Biotechnology$50M
- IGCIGC Pharma, Inc.Biotechnology$20M
- INTSIntensity Therapeutics, Inc.Biotechnology$8M
- NRSNNeuroSense Therapeutics Ltd.Biotechnology$3M
- PLURPluri Inc.Biotechnology$11M
More Biotechnology companies
- BTC.AXBTC Health LimitedASX
- BVAXFBioVaxys Technology Corp.OTC$3M
- BVNKFBavarian Nordic A/SOTC$2.4B
- BVNRYBavarian Nordic A/SOTC$2.4B
- BXPHFBotanix Pharmaceuticals LimitedOTC$89M
- BXRXQBaudax Bio, Inc.OTC$436
- BYSIBeyondSpring Inc.NASDAQ$24M
- ARUXFAcrux LimitedOTC$2M
- ARVNArvinas, Inc.NASDAQ$443M
- ARWRArrowhead Pharmaceuticals, Inc.NASDAQ$6.2B
- ASBPAspire Biopharma Holdings, Inc.NASDAQ$929,898
- ASBPWAspire Biopharma Holdings, Inc.NASDAQ$134,572
ETFs holding Nutriband Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets
- VXFVanguard Extended Market ETF$30.2B in assets
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets
- VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets
- VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets
- VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets
- VCNS.TOVanguard Conservative ETF Portfolio$977M in assets
Largest holders first, then the funds most concentrated in NTRBW.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Nutriband Inc., and how their positions are changing. At a $76.8M market value, institutional positions materially move Nutriband Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Nutriband Inc. executives and directors. Shares of Nutriband Inc. have traded between $0.25 and $2.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Nutriband Inc.. Coverage tracks Nutriband Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Nutriband Inc.